Medicure and Nexus agree Aggrastat generic licence

US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Nexus and Nevakar face off over hypotension drug

19 August 2021 Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.

Americas

Federal Circuit invalidates cardiovascular diagnostics patents

19 June 2017 The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.

Americas

Novartis in $1bn cardiovascular deal with Ionis and Akcea

20 February 2017 Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Medicure and Nexus agree Aggrastat generic licence

More on this story

Editor's picks

Editor's picks

More features